Quotazioni in diretta

ALLO Allogene Therapeutics Inc

2,73

-0,13 (-4,55%)

10 Mag 2024 - Chiuso

Dati in Delay di 15 minuti

Swaap v2 Launches: Revolutionizing DeFi Market Making with Secure, Autopilot Strategies

Paris, France, July 10th, 2023, Chainwire Leveraging its successful $4.5m fundraising, Swaap launches its v2 protocol, bringing easy-to-use and powerful ... Read more
https://www.valuewalk.com/swaap-v2-launches-revolutionizing-defi-market-making-with-secure-autopilot-strategies/

Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Apr 2024 a Mag 2024

Clicca qui per i Grafici di Allogene Therapeutics

Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Mag 2023 a Mag 2024

Clicca qui per i Grafici di Allogene Therapeutics

Notizie Allogene Therapeutics Inc - ALLO

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Lunedì 6 Maggio 2024 (5 giorni fa) • GlobeNewswire Inc.

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Venerdì 26 Aprile 2024 (2 settimane fa) • GlobeNewswire Inc.

Allogene Therapeutics Announces Q2 Investor Conference Participation
Martedì 9 Aprile 2024 (1 mese fa) • GlobeNewswire Inc.

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Giovedì 14 Marzo 2024 (2 mesi fa) • GlobeNewswire Inc.

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Martedì 12 Marzo 2024 (2 mesi fa) • GlobeNewswire Inc.

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Martedì 5 Marzo 2024 (2 mesi fa) • GlobeNewswire Inc.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
Mercoledì 28 Febbraio 2024 (2 mesi fa) • GlobeNewswire Inc.

Form 8-K - Current report
Venerdì 16 Febbraio 2024 (3 mesi fa) • Edgar (US Regulatory)

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Venerdì 16 Febbraio 2024 (3 mesi fa) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 31 Gennaio 2024 (3 mesi fa) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercoledì 24 Gennaio 2024 (4 mesi fa) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Lunedì 22 Gennaio 2024 (4 mesi fa) • Edgar (US Regulatory)

Più Allogene Therapeutics Inc Articoli Notizie

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea